Arecor
Arecor is dedicated to transforming patient care by developing innovative medicines that address significant unmet needs in high-value markets. They leverage their proprietary Arestat™ technology platform to develop enhanced therapeutic medicines, particularly for diabetes and obesity, and collaborate with leading pharmaceutical and medtech companies. Their technology is validated and backed by a robust intellectual property portfolio.
Industries
Nr. of Employees
small (1-50)
Arecor
Products
Ultra-rapid-acting insulin candidates (early clinical)
Insulin formulations engineered for faster onset of action; progressed through Phase I clinical evaluation.
Oral peptide and GLP‑1 formulations (developmental)
Formulations intended to enable oral dosing of peptide therapeutics, including GLP‑1 analogues with enhanced bioavailability.
Thermostable insulin formulations for device delivery (developmental)
Formulations developed to provide thermal stability for insulin intended for implantable pump or device-based delivery.
Enhanced formulation for monoclonal antibody obesity candidate
Formulation development work to improve properties of a monoclonal antibody candidate for obesity indications.
Ultra-rapid-acting insulin candidates (early clinical)
Insulin formulations engineered for faster onset of action; progressed through Phase I clinical evaluation.
Oral peptide and GLP‑1 formulations (developmental)
Formulations intended to enable oral dosing of peptide therapeutics, including GLP‑1 analogues with enhanced bioavailability.
Thermostable insulin formulations for device delivery (developmental)
Formulations developed to provide thermal stability for insulin intended for implantable pump or device-based delivery.
Enhanced formulation for monoclonal antibody obesity candidate
Formulation development work to improve properties of a monoclonal antibody candidate for obesity indications.
Services
Formulation development for peptides and proteins
Development of stable formulations for peptides and proteins to enable alternative administration routes and improve product stability.
Clinical development support (Phase I)
Support for preparation and submission of clinical trial applications and conduct of Phase I studies, including data presentation at scientific meetings.
Collaborative formulation studies and licensing
Exclusive and non‑exclusive formulation study collaborations, technology licensing, and transfers of programme rights to partners.
Analytical stability testing and excipient screening
Analytical testing services to assess protein stability and screen excipients to optimise formulation performance.
Formulation development for peptides and proteins
Development of stable formulations for peptides and proteins to enable alternative administration routes and improve product stability.
Clinical development support (Phase I)
Support for preparation and submission of clinical trial applications and conduct of Phase I studies, including data presentation at scientific meetings.
Collaborative formulation studies and licensing
Exclusive and non‑exclusive formulation study collaborations, technology licensing, and transfers of programme rights to partners.
Analytical stability testing and excipient screening
Analytical testing services to assess protein stability and screen excipients to optimise formulation performance.
Expertise Areas
- Protein and peptide formulation
- Oral peptide delivery
- Insulin formulation for diabetes (ultra-rapid and ultra‑concentrated)
- Thermostable formulations for device-based delivery
Key Technologies
- Protein stabilisation formulation platforms
- Oral peptide formulation technologies
- Thermostabilisation methods for biologics
- Ultra-rapid-acting insulin formulation methods